Race/Ethnicity-Specific Association of Vitamin D and Global DNA Methylation: Cross-Sectional and Interventional Findings.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Understanding of the influence of vitamin D deficiency on epigenome will provide novel insights into the chronic disease risk.

Who Took Part

By PubMed's age tags, the people studied were adults, both men and women.

A two-stage design, cross-sectional observation followed by a 16 week randomized, double- blinded, placebo-controlled trial (RCT) of vitamin D3 supplementation, was undertaken.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

Global DNA methylation level (percentage of 5-methylcytosine, %5-mC) was quantified using leukocyte DNA with the MethylFlashTM Methylated DNA Quantification kit (Epigentek).

What Was Measured

PubMed files the paper under topics including Cross-Sectional Studies, DNA Methylation, Ethnicity, Racial Groups and Vitamin D.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2016 (PloS one), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.